PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing

Join us for this live interactive CME/CE/CPE-certified symposium at SABCS 2018! Expert faculty will provide their perspectives on PARP inhibitors for breast cancer, including insights into their mechanism of action and unique clinical characteristics, integration into current clinical management strategies based on available supporting evidence, and emerging approaches to enhance the utility of these agents for patients with breast cancer.

Held in conjunction with SABCS® 2018

Thank you for your interest in the PARP Inhibitors Symposium! Though pre-registration is now closed, we do welcome on-site registrations. Please come to the San Antonio Marriott Rivercenter, Grand Ballroom Foyer, Salons EF (third floor) and see our on-site registration staff. Remember to bring your SABCS badge with you to expedite your registration. 

 

Agenda

8:00 PM Welcome and Introduction

8:05 PM Understanding the Rationale and Mechanism of Action for PARP Inhibition in MBC

8:25 PM Integrating PARP Inhibition Into Clinical Management of Patients With MBC

8:55 PM Future Directions in PARP Inhibitors in Breast Cancer: Where Do We Go From Here?

9:20 PM Final Thoughts and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Lee Schwartzberg, MD, FACP

Executive Director
West Cancer Center
Germantown, Tennessee
Chief, Division of Hematology/Oncology
Professor of Medicine
University of Tennessee Health Science Center
Memphis, Tennessee

Faculty
Judy E. Garber, MD, MPH

Director, Center for Cancer Genetics and Prevention
Chief, Division of Cancer Genetics and Prevention
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty
Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

CME

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

Target Audience 
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with metastatic breast cancer.

Learning Objectives

  • Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer
  • Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors
  • Integrate single-agent PARP inhibitors into the treatment of appropriately selected patients with metastatic breast cancer
  • Refer eligible patients with metastatic breast cancer to clinical trials of single-agent PARP inhibitors and combinations of PARP inhibitors with other anticancer therapies

Accreditation

Physician Continuing Medical Education

Accreditation Statement
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement
The National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Pharmacists


The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NCCN designates this knowledge-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credits (Universal Activity Number: 0836-9999-18-132-L01-P).

Attention Pharmacists:

You must complete the post-test and evaluation within 30 days of the activity.  Continuing pharmacy education credit is reported to CPE Monitor once the post-test and evaluation are completed.  Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit can NOT be reported.  If you have not already done so, please complete your e-profile at http://www.nabp.net/ to obtain your NABP e-Profile ID.

Disclosure of Conflicts of Interest
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Disclosure of Unlabeled Use 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.